Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Reporters to mark and eliminate basal or luminal epithelial cells in culture and in vivo.

Sonzogni O, Haynes J, Seifried LA, Kamel YM, Huang K, BeGora MD, Yeung FA, Robert-Tissot C, Heng YJ, Yuan X, Wulf GM, Kron KJ, Wagenblast E, Lupien M, Kislinger T, Hannon GJ, Muthuswamy SK.

PLoS Biol. 2018 Jun 20;16(6):e2004049. doi: 10.1371/journal.pbio.2004049. eCollection 2018 Jun.

2.

Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.

Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC.

Cancer Discov. 2018 Mar;8(3):354-369. doi: 10.1158/2159-8290.CD-17-0679. Epub 2017 Dec 4. Erratum in: Cancer Discov. 2018 Aug;8(8):1044.

PMID:
29203461
3.

Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland.

Breitkopf SB, Taveira MO, Yuan M, Wulf GM, Asara JM.

Sci Rep. 2017 Nov 6;7(1):14503. doi: 10.1038/s41598-017-15132-y.

4.

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.

de Oliveira Taveira M, Nabavi S, Wang Y, Tonellato P, Esteva FJ, Cantley LC, Wulf GM.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1255-1262. doi: 10.1007/s00432-017-2358-x. Epub 2017 Feb 28.

5.

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.

Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E.

Ann Oncol. 2017 Mar 1;28(3):512-518. doi: 10.1093/annonc/mdw672.

6.

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.

Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf GM, English J, Kirschmeier PT, Velculescu VE, Paweletz C, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R.

Clin Cancer Res. 2017 Mar 1;23(5):1263-1273. doi: 10.1158/1078-0432.CCR-16-1237. Epub 2016 Aug 29.

7.

Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.

Juvekar A, Hu H, Yadegarynia S, Lyssiotis CA, Ullas S, Lien EC, Bellinger G, Son J, Hok RC, Seth P, Daly MB, Kim B, Scully R, Asara JM, Cantley LC, Wulf GM.

Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4338-47. doi: 10.1073/pnas.1522223113. Epub 2016 Jul 8.

8.

Epstein-Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation.

Hu H, Luo ML, Desmedt C, Nabavi S, Yadegarynia S, Hong A, Konstantinopoulos PA, Gabrielson E, Hines-Boykin R, Pihan G, Yuan X, Sotiriou C, Dittmer DP, Fingeroth JD, Wulf GM.

EBioMedicine. 2016 Jul;9:148-160. doi: 10.1016/j.ebiom.2016.05.025. Epub 2016 May 21.

9.

Deletion of the gene Pip4k2c, a novel phosphatidylinositol kinase, results in hyperactivation of the immune system.

Shim H, Wu C, Ramsamooj S, Bosch KN, Chen Z, Emerling BM, Yun J, Liu H, Choo-Wing R, Yang Z, Wulf GM, Kuchroo VK, Cantley LC.

Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7596-601. doi: 10.1073/pnas.1600934113. Epub 2016 Jun 16.

10.

Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton.

Hu H, Juvekar A, Lyssiotis CA, Lien EC, Albeck JG, Oh D, Varma G, Hung YP, Ullas S, Lauring J, Seth P, Lundquist MR, Tolan DR, Grant AK, Needleman DJ, Asara JM, Cantley LC, Wulf GM.

Cell. 2016 Jan 28;164(3):433-46. doi: 10.1016/j.cell.2015.12.042.

11.

Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors.

Emerling BM, Hurov JB, Poulogiannis G, Tsukazawa KS, Choo-Wing R, Wulf GM, Bell EL, Shim HS, Lamia KA, Rameh LE, Bellinger G, Sasaki AT, Asara JM, Yuan X, Bullock A, Denicola GM, Song J, Brown V, Signoretti S, Cantley LC.

Cell. 2013 Nov 7;155(4):844-57. doi: 10.1016/j.cell.2013.09.057.

12.

PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells.

Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, DePinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Vander Heiden MG.

Cell. 2013 Oct 10;155(2):397-409. doi: 10.1016/j.cell.2013.09.025.

13.

Closing escape routes: inhibition of IL-8 signaling enhances the anti-tumor efficacy of PI3K inhibitors.

Juvekar A, Wulf GM.

Breast Cancer Res. 2013 Apr 8;15(2):308. doi: 10.1186/bcr3400.

14.

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM.

Cancer Discov. 2012 Nov;2(11):1048-63. doi: 10.1158/2159-8290.CD-11-0336. Epub 2012 Aug 22.

15.

The amplifier effect: how Pin1 empowers mutant p53.

Hu H, Wulf GM.

Breast Cancer Res. 2011 Oct 13;13(5):315. doi: 10.1186/bcr2941.

16.

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, Yu D, Esteva FJ.

J Clin Oncol. 2011 Aug 10;29(23):3126-32. doi: 10.1200/JCO.2010.32.2321. Epub 2011 Jul 5.

17.
18.

Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review.

Pories SE, Wulf GM.

Breast Cancer (Dove Med Press). 2010 Jun 21;2:37-44. Review.

19.

Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers.

Burga LN, Tung NM, Troyan SL, Bostina M, Konstantinopoulos PA, Fountzilas H, Spentzos D, Miron A, Yassin YA, Lee BT, Wulf GM.

Cancer Res. 2009 Feb 15;69(4):1273-8. doi: 10.1158/0008-5472.CAN-08-2954. Epub 2009 Feb 3.

20.

Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.

Lam PB, Burga LN, Wu BP, Hofstatter EW, Lu KP, Wulf GM.

Mol Cancer. 2008 Dec 15;7:91. doi: 10.1186/1476-4598-7-91.

21.

Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage.

Wulf GM, Liou YC, Ryo A, Lee SW, Lu KP.

J Biol Chem. 2002 Dec 13;277(50):47976-9. Epub 2002 Oct 17.

22.
23.
24.
25.

cDNA cloning of a human mRNA preferentially expressed in hematopoietic cells and with homology to a GDP-dissociation inhibitor for the rho GTP-binding proteins.

Lelias JM, Adra CN, Wulf GM, Guillemot JC, Khagad M, Caput D, Lim B.

Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1479-83.

Supplemental Content

Support Center